AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Syndax Pharmaceuticals (SNDX) Soars 13.9% Despite Q4 Loss
Generated by AI AgentAinvest Movers Radar
Tuesday, Apr 8, 2025 4:51 am ET1min read
Syndax Pharmaceuticals, Inc. (SNDX) surged 13.9% in pre-market trading on April 8, 2025, marking a significant uptick in investor interest.
Syndax Pharmaceuticals reported a Q4 loss, falling short of revenue estimates. The company's earnings and revenue surprises were -1.85% and 65.45%, respectively, indicating a challenging quarter.
Shares of
have experienced a significant decline, dropping over 50% due to the lower complete response rate of Revuforj compared to Kura Oncology's ziftomenib in treating relapsed/refractory NPM1-mutated acute myeloid leukemia.Bryce Point Capital LLC acquired a new stake in Syndax Pharmaceuticals during the fourth quarter, demonstrating continued institutional interest in the company.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
NLY Shares Soar 2.51% Intraday on $2.5B Equity Offering Program
Dec.22 2025
Lam Research Soars 13.09% on AI/HPC Demand, Analyst Upgrades
Dec.22 2025
WisdomTree Shares Surge 8.75% as Japan Hedged ETF Outperforms Unhedged 8x in 5 Years
Dec.22 2025
FBS Global Shares Rally 18.39% on Earnings Turnaround, Seven-Day Gains Reach 14.23%
Dec.22 2025
Firefly Aerospace Share Price Rallies 16.59% Intraday on Russell Index Inclusion, New COO Appointment
Dec.22 2025
Aime Insights
How might the recent executive share sales at Rimini Street impact investor sentiment towards the company?
What is the current sentiment towards safe-haven assets like gold and silver?
How could Nvidia's planned shipment of H200 chips to China in early 2026 affect the global semiconductor market?
How should investors position themselves in the face of a potential market correction?
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet